Biomarin Pharmaceutical Inc (BMRN)

Working capital turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 2,830,220 2,731,722 2,563,532 2,443,023 2,373,030 2,261,604 2,184,719 2,123,138 2,059,481 1,999,471 1,903,678 1,871,615 1,827,451 1,829,463 1,891,778 1,815,339 1,822,817 1,822,364 1,813,337 1,772,797
Total current assets US$ in thousands 3,232,430 3,056,590 3,259,630 2,985,010 2,956,090 2,955,310 2,950,120 2,842,100 2,751,460 2,682,700 2,517,600 2,394,020 2,274,380 2,311,570 2,357,840 2,288,770 2,342,220 2,738,980 2,647,570 2,116,250
Total current liabilities US$ in thousands 606,988 715,658 1,067,340 1,087,900 1,177,020 1,163,220 597,231 598,231 588,884 521,020 464,727 490,418 546,497 514,898 443,344 430,035 492,548 854,693 813,302 820,470
Working capital turnover 1.08 1.17 1.17 1.29 1.33 1.26 0.93 0.95 0.95 0.92 0.93 0.98 1.06 1.02 0.99 0.98 0.99 0.97 0.99 1.37

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $2,830,220K ÷ ($3,232,430K – $606,988K)
= 1.08

The working capital turnover ratio for Biomarin Pharmaceutical Inc fluctuated over the period from March 31, 2020, to December 31, 2024. The ratio measures how effectively the company is using its working capital to generate sales revenue.

Initially, the working capital turnover was 1.37 on March 31, 2020, indicating that Biomarin Pharmaceutical Inc generated $1.37 in revenue for every dollar of working capital invested. However, the ratio decreased to 0.99 by June 30, 2020, and remained relatively stable around this level until September 30, 2021.

From September 30, 2021, the working capital turnover started to improve, reaching 1.33 by December 31, 2023. This suggests that the company was becoming more efficient in utilizing its working capital to generate sales.

However, the ratio declined to 1.08 by December 31, 2024. This decrease may indicate that Biomarin Pharmaceutical Inc faced challenges in managing its working capital efficiently to support its revenue generation activities.

Overall, the working capital turnover ratio for Biomarin Pharmaceutical Inc showed variability over the analyzed period, reflecting fluctuations in the company's ability to effectively leverage its working capital for revenue generation.